CDSCO approves India’s first dengue vaccine
The Central Drugs Standard Control Organisation (CDSCO) approved India's first dengue vaccine, a tetravalent live-attenuated vaccine developed using recombinant DNA technology
The vaccine is approved for individuals aged 4 to 60 years, administered as two subcutaneous doses three months apart
Approval followed Phase III trials conducted in the Indian population alongside multi-country trials spanning eight dengue-endemic and non-endemic countries
The vaccine has already received approval in over 40 countries and WHO prequalification, with tens of millions of doses distributed globally before the Indian approval
CDSCO and the New Drug Approval Process in India
The Central Drugs Standard Control Organisation, headquartered in New Delhi under the Directorate General of Health Services, Ministry of Health and Family Welfare, is India's National Regulatory Authority for drugs and vaccines. It functions under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, with new drug and clinical trial approvals now governed by the New Drugs and Clinical Trials Rules, 2019.
Key Details
- The 2019 Rules replaced Part XA and Schedule Y of the 1945 Rules and introduced defined approval timelines — a maximum of 90 days for most new drug applications, and 30 days for drugs researched and manufactured in India
- CDSCO approval is distinct from WHO prequalification; a vaccine already used abroad still requires an independent India-specific regulatory clearance before domestic use
- The Subject Expert Committee (SEC) under CDSCO evaluates safety and efficacy data before a New Drug is permitted for marketing in India
Although this dengue vaccine already had international approval and WHO prequalification, it required a full CDSCO review — including India-specific Phase III data — before being cleared for use, illustrating how domestic regulatory approval operates independently of global prequalification.
Dengue Virus Serotypes and Vaccine Design Challenge
Dengue is caused by four genetically distinct but related serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), all of which co-circulate in India. This multi-serotype structure is what makes dengue vaccine development difficult: a vaccine must protect against all four serotypes simultaneously (hence "tetravalent"), because sequential infection with a different serotype increases the risk of severe disease (antibody-dependent enhancement).
Key Details
- All four DENV serotypes are known to circulate in India, with different serotypes dominating in different states and years
- The approved vaccine uses a live-attenuated, recombinant platform: it is built on a weakened DENV-2 backbone with genes from the other three serotypes engineered in, produced using Vero cell culture
- Long-term Phase III (TIDES) trial data reported efficacy of roughly 61% against confirmed dengue and over 84% against dengue-related hospitalisation, with sustained protection observed up to seven years in some cohorts [Unverified — exact efficacy figures should be cross-checked against the CDSCO approval dossier]
The vaccine's tetravalent, multi-serotype design directly addresses India's specific epidemiological profile, where all four serotypes circulate, unlike some dengue-endemic regions dominated by a single serotype.
National Vector Borne Disease Control Programme (NVBDCP)
The NVBDCP, under the Ministry of Health and Family Welfare, is India's umbrella programme for surveillance and control of vector-borne diseases including dengue, malaria, chikungunya, and Japanese encephalitis. It relies primarily on vector control (source reduction, larvicide use) and clinical case management, since until now no dengue vaccine was licensed for use in the national programme.
Key Details
- Dengue control in India has historically depended on non-pharmaceutical interventions: Aedes aegypti mosquito control, case surveillance, and early clinical management, since there was no approved vaccine
- The introduction of a licensed vaccine creates a potential new pillar for the NVBDCP's dengue strategy, though initial rollout is expected to be through the private market rather than immediate inclusion in the Universal Immunization Programme [Unverified]
- Vaccine platform comparison: live-attenuated (this vaccine, and the earlier globally used CYD-TDV/Dengvaxia) versus inactivated or subunit platforms, which are typically considered safer for use in dengue-naive populations
This is the first dengue vaccine available through India's regulatory system, marking a potential shift from purely vector-control-based dengue management toward a combined vaccination-plus-vector-control approach.
- Vaccine platform: tetravalent, live-attenuated, recombinant DNA technology on a DENV-2 backbone, produced in Vero cells
- Approved age group: 4–60 years; dosing schedule: two 0.5 ml subcutaneous doses, 3 months apart
- Regulatory basis: Drugs and Cosmetics Act, 1940 and Rules, 1945, via the New Drugs and Clinical Trials Rules, 2019
- Prior global status: approved in 40+ countries with WHO prequalification before Indian approval
- Four dengue serotypes: DENV-1, DENV-2, DENV-3, DENV-4 — all circulate in India